Sin-Hee Park1, Muhammad Akmal Farooq1, Sébastien Gaertner1,2, Christophe Bruckert1, Abdul Wahid Qureshi1, Hyun-Ho Lee1, Djamel Benrahla1, Brigitte Pollet3, Dominique Stephan1,2, Patrick Ohlmann4, Jean-Marc Lessinger5, Eric Mayoux6, Cyril Auger1, Olivier Morel1,4, Valérie B Schini-Kerth7. 1. INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, FMTS, Strasbourg, France. 2. Hôpitaux Universitaires de Strasbourg, Service des Maladies Vasculaires - Hypertension Artérielle, Strasbourg, France. 3. UMR CNRS 7021 Laboratoire de Bioimagerie et Pathologies, Strasbourg, France. 4. Hôpitaux Universitaires de Strasbourg, Service de Cardiologie, Strasbourg, France. 5. Laboratory of Biochemistry and Molecular Biology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France. 6. Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany. 7. INSERM (French National Institute of Health and Medical Research), UMR 1260, Regenerative Nanomedicine, FMTS, Strasbourg, France. valerie.schini-kerth@unistra.fr.
Abstract
BACKGROUND: Empagliflozin (empa), a selective sodium-glucose cotransporter (SGLT)2 inhibitor, reduced cardiovascular mortality and hospitalization for heart failure in patients with type 2 diabetes at high cardiovascular risk independent of glycemic control. The cardiovascular protective effect of empa was evaluated in an experimental model of metabolic syndrome, the obese ZSF1 rat, and its' lean control. METHODS: Lean and obese ZSF1 rats were either non-treated or treated with empa (30 mg/kg/day) for 6 weeks. Vascular reactivity was assessed using mesenteric artery rings, systolic blood pressure by tail-cuff sphygmomanometry, heart function and structural changes by echocardiography, and protein expression levels by Western blot analysis. RESULTS: Empa treatment reduced blood glucose levels from 275 to 196 mg/dl in obese ZSF1 rats whereas normoglycemia (134 mg/dl) was present in control lean ZSF1 rats and was unaffected by empa. Obese ZSF1 rats showed increased systolic blood pressure, and blunted endothelium-dependent relaxations associated with the appearance of endothelium-dependent contractile responses (EDCFs) compared to control lean rats. These effects were prevented by the empa treatment. Obese ZSF1 rats showed increased weight of the heart and of the left ventricle volume without the presence of diastolic or systolic dysfunction, which were improved by the empa treatment. An increased expression level of senescence markers (p53, p21, p16), tissue factor, VCAM-1, SGLT1 and SGLT2 and a down-regulation of eNOS were observed in the aortic inner curvature compared to the outer one in the control lean rats, which were prevented by the empa treatment. In the obese ZSF1 rats, no such effects were observed. The empa treatment reduced the increased body weight and weight of lungs, spleen, liver and perirenal fat, hyperglycemia and the increased levels of total cholesterol and triglycerides in obese ZSF1 rats, and increased blood ketone levels and urinary glucose excretion in control lean and obese ZSF1 rats. CONCLUSION: Empa reduced glucose levels by 28% and improved both endothelial function and cardiac remodeling in the obese ZSF1 rat. Empa also reduced the increased expression level of senescence, and atherothrombotic markers at arterial sites at risk in the control lean, but not obese, ZSF1 rat.
BACKGROUND:Empagliflozin (empa), a selective sodium-glucose cotransporter (SGLT)2 inhibitor, reduced cardiovascular mortality and hospitalization for heart failure in patients with type 2 diabetes at high cardiovascular risk independent of glycemic control. The cardiovascular protective effect of empa was evaluated in an experimental model of metabolic syndrome, the obese ZSF1 rat, and its' lean control. METHODS: Lean and obese ZSF1 rats were either non-treated or treated with empa (30 mg/kg/day) for 6 weeks. Vascular reactivity was assessed using mesenteric artery rings, systolic blood pressure by tail-cuff sphygmomanometry, heart function and structural changes by echocardiography, and protein expression levels by Western blot analysis. RESULTS:Empa treatment reduced blood glucose levels from 275 to 196 mg/dl in obese ZSF1 rats whereas normoglycemia (134 mg/dl) was present in control lean ZSF1 rats and was unaffected by empa. Obese ZSF1 rats showed increased systolic blood pressure, and blunted endothelium-dependent relaxations associated with the appearance of endothelium-dependent contractile responses (EDCFs) compared to control lean rats. These effects were prevented by the empa treatment. Obese ZSF1 rats showed increased weight of the heart and of the left ventricle volume without the presence of diastolic or systolic dysfunction, which were improved by the empa treatment. An increased expression level of senescence markers (p53, p21, p16), tissue factor, VCAM-1, SGLT1 and SGLT2 and a down-regulation of eNOS were observed in the aortic inner curvature compared to the outer one in the control lean rats, which were prevented by the empa treatment. In the obese ZSF1 rats, no such effects were observed. The empa treatment reduced the increased body weight and weight of lungs, spleen, liver and perirenal fat, hyperglycemia and the increased levels of total cholesterol and triglycerides in obese ZSF1 rats, and increased blood ketone levels and urinary glucose excretion in control lean and obese ZSF1 rats. CONCLUSION:Empa reduced glucose levels by 28% and improved both endothelial function and cardiac remodeling in the obese ZSF1 rat. Empa also reduced the increased expression level of senescence, and atherothrombotic markers at arterial sites at risk in the control lean, but not obese, ZSF1 rat.
Authors: Husam M Salah; Subodh Verma; Carlos G Santos-Gallego; Ankeet S Bhatt; Muthiah Vaduganathan; Muhammad Shahzeb Khan; Renato D Lopes; Subhi J Al'Aref; Darren K McGuire; Marat Fudim Journal: J Cardiovasc Transl Res Date: 2022-03-15 Impact factor: 4.132
Authors: Seshagiri Rao Nandula; Nabanita Kundu; Hassan B Awal; Beda Brichacek; Mona Fakhri; Nikhila Aimalla; Adrian Elzarki; Richard L Amdur; Sabyasachi Sen Journal: Cardiovasc Diabetol Date: 2021-02-13 Impact factor: 9.951
Authors: B Gaborit; P Ancel; F Kober; A Dutour; A E Abdullah; F Maurice; I Abdesselam; A Calen; A Soghomonian; M Houssays; I Varlet; M Eisinger; A Lasbleiz; F Peiretti; C E Bornet; Y Lefur; L Pini; S Rapacchi; M Bernard; N Resseguier; P Darmon Journal: Cardiovasc Diabetol Date: 2021-03-01 Impact factor: 9.951
Authors: João Pedro Ferreira; Subodh Verma; David Fitchett; Anne Pernille Ofstad; Sabine Lauer; Isabella Zwiener; Jyothis George; Christoph Wanner; Bernard Zinman; Silvio E Inzucchi Journal: Cardiovasc Diabetol Date: 2020-11-26 Impact factor: 9.951